Your session is about to expire
← Back to Search
E2814 for Alzheimer's Disease
Study Summary
This trial is testing a new drug for Alzheimer's Disease. The goal is to see if it is safe and if it affects a protein in the brain that is linked to the disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not used effective birth control in the last 3 months.I have a history of HIV, recent hepatitis B, untreated hepatitis C, or a CNS spirochete infection.I have a confirmed mutation in PSEN1, APP, or PSEN2 linked to early-onset Alzheimer's.My brain MRI shows signs that might suggest a dementia diagnosis other than Alzheimer's.I haven't had a serious illness or infection needing treatment in the last 8 weeks.I am scheduled for surgery under general anesthesia during the study period.I am not pregnant or breastfeeding.I have no neurological conditions affecting my cognition besides Alzheimer's.I do not have any mental health conditions that could affect my participation.I do not have a bleeding disorder nor am I on long-term blood thinners.I have not had a stroke, mini-stroke, or seizures in the last year.My HgbA1c is over 8% or I have poorly controlled diabetes.I have a history of significant blockages in my neck or back arteries, or risk factors for stroke.I do not have any medical devices or metal implants that prevent me from having an MRI.I haven't had cancer, except for certain skin, prostate, or breast cancers, in the last 3 years.My immune system disease is not well-controlled or needs strong medication.I am between 18 and 80 years old.
- Group 1: Cohort B: E2814
- Group 2: Cohort A, Phase 1b and 2: E2814
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are new participants able to join this clinical investigation?
"Clinicaltrials.gov does not list this clinical trial as actively recruiting patients at the moment, with its original post date being June 28th 2021 and latest update on May 24th 2022. However, there are still 980 other studies that are looking for participants to join their trials."
Is my participation in this medical study feasible?
"This clinical trial is recruiting 8 individuals aged 18 to 80 who have been diagnosed with Alzheimer's disease. To qualify, candidates must be either male or female and possess a confirmed mutation of the PSEN1, APP, or PSEN2 gene related to DIAD. Additionally, their CDR-SB score should range between 5 and 12 at screening; they need evidence of amyloid positivity in an amyloid PET scan; consent to MRI, lumbar puncture (LP), and other study tests/evaluations; provide an informant that can accurately assess cognitive/functional abilities; plus agree to supply necessary information during visits requiring"
Is the age requirement for this research study limited to individuals 40 years and younger?
"This research necessitates that the participants are between 18 and 80 years of age, with 44 trials for minors and nearly a thousand studies dedicated to those 65 or over."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger